It is overexpressed in a variety of tumours such as prostate cancer and ovarian cancer, and its blockade can inhibit tumour metastasis by enhancing CD8 + T-cell-mediated antitumour immunity [17, 18]. This evidence concerns the gene CD8A and prostate carcinoma.